Artículos por temáticas

Whole exome sequencing identifies a homozygous POLG2 missense variant in an adult patient presenting with optic atrophy, movement disorders, premature ovarian failure and mitochondrial DNA depletion.

Dosekova P, Dubiel A, Karlowicz A, Zietkiewicz S, Rydzanicz M, Habalova V, Pienkowski VM, Skirkova M, Han V, Mosejova A, Gdovinova Z, Kaliszewska M, Tońska K, Szymanski MR, Skorvanek M, Ploski R.

Eur J Med Genet. 2020 Apr;63(4):103821. doi: 10.1016/j.ejmg.2019.103821. Epub 2019 Nov 26.

Determinants of ferritin response to oral iron supplementation in children with sleep movement disorders.

DelRosso LM, Yi T, Chan JHM, Wrede JE, Lockhart CT, Ferri R.

Sleep. 2020 Mar 12;43(3). pii: zsz234. doi: 10.1093/sleep/zsz234.

The expanding spectrum of movement disorders in genetic epilepsies.

Papandreou A, Danti FR, Spaull R, Leuzzi V, Mctague A, Kurian MA.

Dev Med Child Neurol. 2020 Feb;62(2):178-191. doi: 10.1111/dmcn.14407. Epub 2019 Nov 29. Review.

Functionally meaningful rating scales in progressive pediatric movement disorders.

Perlman S.

Dev Med Child Neurol. 2020 Feb;62(2):157. doi: 10.1111/dmcn.14372. Epub 2019 Oct 3. No abstract available.

Quality of life in functional movement disorders is as altered as in organic movement disorders.

Gendre T, Carle G, Mesrati F, Hubsch C, Mauras T, Roze E, Houot M, Degos B, Garcin B.

J Psychosom Res. 2019 Jan;116:10-16. doi: 10.1016/j.jpsychores.2018.11.006. Epub 2018 Nov 12.

Roles of the M(4) acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Moehle MS, Conn PJ.

Mov Disord. 2019 Jun 18. doi: 10.1002/mds.27740. [Epub ahead of print]

Abnormal Eye Movements in Parkinsonism and Movement Disorders.

Jung I, Kim JS.

J Mov Disord. 2019 Jan;12(1):1-13. doi: 10.14802/jmd.18034. Epub 2019 Jan 30.

Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.

Peralta C, Biafore F, Depetris TS, Bastianello M.

Curr Neurol Neurosci Rep. 2019 Jun 29;19(8):56. doi: 10.1007/s11910-019-0966-3. Review.

Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension.

Dreissen YEM, Dijk JM, Gelauff JM, Zoons E, van Poppelen D, Contarino MF, Zutt R, Post B, Munts AG, Speelman JD, Cath DC, de Haan RJ, Koelman JH, Tijssen MAJ.

J Neurol Neurosurg Psychiatry. 2019 Jun 20. pii: jnnp-2018-320071. doi: 10.1136/jnnp-2018-320071. [Epub ahead of print]

A Curious Case of Transient Movement Disorder.

Kennedy KN, Wang YD.

Am J Med. 2019 May;132(5):585-587. doi: 10.1016/j.amjmed.2018.12.024. Epub 2019 Jan 9. No abstract available.

Movement Disorders Emergencies.

Rajan S, Kaas B, Moukheiber E.

Semin Neurol. 2019 Feb;39(1):125-136. doi: 10.1055/s-0038-1677050. Epub 2019 Feb 11.

Neuroimaging in Functional Movement Disorders.

Roelofs JJ, Teodoro T, Edwards MJ.

Curr Neurol Neurosci Rep. 2019 Feb 12;19(3):12. doi: 10.1007/s11910-019-0926-y. Review.

Forelimb Movement Disorder in Rat Experimental Model.

Marešová D, Kotková K, Kozler P, Pokorný J.

Physiol Res. 2019 Dec 30;68(6):1037-1042. Epub 2019 Oct 25.

Antisense therapies for movement disorders.

Scoles DR, Pulst SM.

Mov Disord. 2019 Aug;34(8):1112-1119. doi: 10.1002/mds.27782. Epub 2019 Jul 8. Review.

The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders.

Latorre A, Rocchi L, Berardelli A, Bhatia KP, Rothwell JC.

Mov Disord. 2019 Jul;34(7):936-949. doi: 10.1002/mds.27736. Epub 2019 Jun 10. Review.